EA036103B1 - Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса - Google Patents

Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса Download PDF

Info

Publication number
EA036103B1
EA036103B1 EA201791067A EA201791067A EA036103B1 EA 036103 B1 EA036103 B1 EA 036103B1 EA 201791067 A EA201791067 A EA 201791067A EA 201791067 A EA201791067 A EA 201791067A EA 036103 B1 EA036103 B1 EA 036103B1
Authority
EA
Eurasian Patent Office
Prior art keywords
dose
drug
formulation
obese
subject
Prior art date
Application number
EA201791067A
Other languages
English (en)
Russian (ru)
Other versions
EA201791067A1 (ru
Inventor
Нейл М. Коуэн
Original Assignee
Эссэнтиалис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55955075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA036103(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эссэнтиалис, Инк. filed Critical Эссэнтиалис, Инк.
Publication of EA201791067A1 publication Critical patent/EA201791067A1/ru
Publication of EA036103B1 publication Critical patent/EA036103B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
EA201791067A 2014-11-14 2015-11-12 Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса EA036103B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462080150P 2014-11-14 2014-11-14
US201562138245P 2015-03-25 2015-03-25
US201562170035P 2015-06-02 2015-06-02
US201562221359P 2015-09-21 2015-09-21
PCT/US2015/060455 WO2016077629A1 (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Publications (2)

Publication Number Publication Date
EA201791067A1 EA201791067A1 (ru) 2017-11-30
EA036103B1 true EA036103B1 (ru) 2020-09-29

Family

ID=55955075

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791067A EA036103B1 (ru) 2014-11-14 2015-11-12 Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса

Country Status (19)

Country Link
US (8) US10058557B2 (enExample)
EP (1) EP3217963B1 (enExample)
JP (4) JP6709226B2 (enExample)
KR (4) KR102323613B1 (enExample)
CN (3) CN113599386B (enExample)
AU (2) AU2015346196B2 (enExample)
BR (1) BR112017009986A2 (enExample)
CA (4) CA3210794A1 (enExample)
DK (1) DK3217963T3 (enExample)
EA (1) EA036103B1 (enExample)
ES (1) ES2806977T3 (enExample)
HU (1) HUE050895T2 (enExample)
IL (1) IL252111B (enExample)
MX (2) MX381305B (enExample)
MY (1) MY187610A (enExample)
NZ (1) NZ768958A (enExample)
PL (1) PL3217963T3 (enExample)
SG (1) SG11201703721SA (enExample)
WO (1) WO2016077629A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510835A (ja) 2004-08-25 2008-04-10 エッセンシャリス，インク． カリウムａｔｐチャンネル開放因子の製剤処方、及びその使用
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
WO2007081521A2 (en) 2006-01-05 2007-07-19 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
KR102323613B1 (ko) 2014-11-14 2021-11-09 에센셜리스 인코포레이티드 프라더-윌리 증후군 또는 스미스-마제니스 증후군을 가지는 대상체를 치료하는 방법
MX375277B (es) * 2016-06-03 2025-03-06 Univ Columbia Métodos para tratar el síndrome de prader-willi
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
US20200093884A1 (en) * 2018-09-20 2020-03-26 Mark C. Manning Stable intranasal formulations of carbetocin
CN111888330B (zh) * 2020-09-18 2022-08-16 常州市第四制药厂有限公司 一种二氮嗪口服混悬溶液及制备方法
AR130798A1 (es) * 2022-10-18 2025-01-22 Rhythm Pharmaceuticals Inc Potenciadores novedosos de los canales de potasio sensibles a atp, su preparación y uso
WO2025057119A1 (en) * 2023-09-15 2025-03-20 Soleno Therapeutics, Inc. Methods of managing glycemic control in prader-willi syndrome patients
WO2025222188A1 (en) * 2024-04-18 2025-10-23 Rhythm Pharmaceuticals, Inc. Novel potassium channel opener compounds and related uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148525A1 (en) * 2004-08-25 2009-06-11 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
US20120053172A1 (en) * 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2986573A (en) 1961-01-18 1961-05-30 Schering Corp Method for the treatment of hypertension
GB8601204D0 (en) 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US5284845A (en) 1991-03-14 1994-02-08 Paulsen Elsa P Use of oral diazoxide for the treatment of disorders in glucose metabolism
US5629045A (en) 1992-09-17 1997-05-13 Richard L. Veech Biodegradable nosiogenic agents for control of non-vertebrate pests
US5399359A (en) 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US6225310B1 (en) * 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
AU4133997A (en) 1996-09-12 1998-04-02 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
US6197765B1 (en) 1999-06-08 2001-03-06 Pnina Vardi Use of diazoxide for the treatment of metabolic syndrome and diabetes complications
WO2002000222A1 (en) 2000-06-26 2002-01-03 Novo Nordisk A/S Use of potassium channel agonists for the treatment of cancer
TW478039B (en) 2001-04-09 2002-03-01 Promos Technologies Inc Phase shift alignment system
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6960346B2 (en) 2002-05-09 2005-11-01 University Of Tennessee Research Foundation Vehicles for delivery of biologically active substances
AU2003287640A1 (en) 2002-11-12 2004-06-03 Collegium Pharmaceutical, Inc. Inertial drug delivery system
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
WO2006000607A1 (es) 2004-06-23 2006-01-05 Neurotec Pharma, S.L. Uso de activadores de los canales de katp (kco), en particular el diazóxido, en el tratamiento de la inflamación crónica de snc asociada a algunas efermedades
CN101043879A (zh) * 2004-08-25 2007-09-26 伊森舍丽斯有限公司 钾atp通道开放剂的药物制剂及其应用
RU2007119315A (ru) * 2004-10-25 2008-11-27 Зольвай Фармасьютиклз Гмбх (De) Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
CN101257897A (zh) * 2005-07-07 2008-09-03 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
WO2007081521A2 (en) 2006-01-05 2007-07-19 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
CA2655144A1 (en) * 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
US20120238554A1 (en) 2007-07-02 2012-09-20 Cowen Neil M Salts of potassium atp channel openers and uses thereof
CN101795691A (zh) 2007-07-02 2010-08-04 伊森舍丽斯有限公司 钾atp通道开放剂的盐及其用途
LT2790721T (lt) * 2011-12-15 2019-02-11 Millendo Therapeutics Sas Neacilinto grelino fragmentai, skirti naudoti preiderio-vilio sindromo gydymui
WO2013130411A1 (en) 2012-02-27 2013-09-06 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
JP2014074004A (ja) * 2012-10-05 2014-04-24 Shinichi Niijima 精神症状の改善剤
US20140364367A1 (en) 2013-06-08 2014-12-11 Sedogen, Llc Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener
KR102323613B1 (ko) 2014-11-14 2021-11-09 에센셜리스 인코포레이티드 프라더-윌리 증후군 또는 스미스-마제니스 증후군을 가지는 대상체를 치료하는 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148525A1 (en) * 2004-08-25 2009-06-11 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
US20120053172A1 (en) * 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
(BAY, H.E. et al.) Diazoxide Choline Controlled Release in Hyperglyceridemic Subjects: Lipid and Other Metabolic Effects. Journal of the American College of Cardiology. 2010. vol 55, no. 10a. [Retrieved on 16 December 2015]. Retrieved from the internet; URL: <https://clinicaltrials.gov/archive/NCT02034071/2014_01_10>; abstract *
(CLINICALTRIALS.GOV) Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome NCT02034071. 10 January 2014. [Retrieved on 16 December 2015]. Retrieved from the internet; URL: <https://clinicaltrials.gov/archive/NCT02034071/2014_01_10>; page 1, brief title, brief summary *
(EIHOLZER, U. et al.) Treatment With Human Growth Hormone in Patients With Prader-Labhart-Willi Syndrome Reduces Body Fat And Increases Muscle Mass And Physical Performance. European Journal of Pediatrics. 1998. vol. 157, no. 5; page 368, second column, third paragraph; page 374, sixth-seventh paragraphs; page 375, first column, fourth paragraph; page 375, second column, fourth paragraph *
(EINSPIELER, C.) Early Behavioural Manifestation of Smith-Magenis Syndrome (Del 17p11.2) in a 4-Month-Old Boy. Developmental Neurorehabilitation. 2012. vol. 15, no. 4; page 313, first column, first paragraph *

Also Published As

Publication number Publication date
US10456408B2 (en) 2019-10-29
IL252111A0 (en) 2017-07-31
MY187610A (en) 2021-10-04
HUE050895T2 (hu) 2021-01-28
JP2023056025A (ja) 2023-04-18
CA2966907A1 (en) 2016-05-19
AU2019202906A1 (en) 2019-05-16
JP2020073566A (ja) 2020-05-14
CA3125839A1 (en) 2016-05-19
JP7232300B2 (ja) 2023-03-02
KR20170082625A (ko) 2017-07-14
KR20230049760A (ko) 2023-04-13
US20250288593A1 (en) 2025-09-18
CA3125839C (en) 2023-10-24
WO2016077629A1 (en) 2016-05-19
US20240207284A1 (en) 2024-06-27
PL3217963T3 (pl) 2020-10-19
EP3217963A4 (en) 2018-07-04
KR102517840B1 (ko) 2023-04-05
AU2019202906B2 (en) 2020-05-21
CN113599386A (zh) 2021-11-05
EP3217963A1 (en) 2017-09-20
CN107106500A (zh) 2017-08-29
JP2017533972A (ja) 2017-11-16
EA201791067A1 (ru) 2017-11-30
JP2021193148A (ja) 2021-12-23
CA3125835A1 (en) 2016-05-19
CA2966907C (en) 2021-09-07
MX393030B (es) 2025-03-24
US20250120979A1 (en) 2025-04-17
US20190105327A1 (en) 2019-04-11
ES2806977T3 (es) 2021-02-19
JP7645913B2 (ja) 2025-03-14
KR102452254B1 (ko) 2022-10-11
US12178823B1 (en) 2024-12-31
MX381305B (es) 2025-03-12
US10874676B2 (en) 2020-12-29
US20180021344A1 (en) 2018-01-25
CA3125835C (en) 2023-01-03
CN113599386B (zh) 2025-12-05
KR20220124289A (ko) 2022-09-13
US20240423996A1 (en) 2024-12-26
JP6955039B2 (ja) 2021-10-27
US20200147100A1 (en) 2020-05-14
US20210322434A1 (en) 2021-10-21
EP3217963B1 (en) 2020-05-20
KR102323613B1 (ko) 2021-11-09
MX2021003982A (es) 2022-06-09
IL252111B (en) 2021-09-30
CN107106500B (zh) 2021-07-30
SG11201703721SA (en) 2017-06-29
CN121910740A (zh) 2026-04-24
NZ731565A (en) 2021-06-25
KR20210134843A (ko) 2021-11-10
US12109216B2 (en) 2024-10-08
BR112017009986A2 (pt) 2018-02-14
MX2017006244A (es) 2018-02-26
KR102598666B1 (ko) 2023-11-07
NZ768958A (en) 2021-07-30
US12419895B1 (en) 2025-09-23
AU2015346196A1 (en) 2017-06-29
US10058557B2 (en) 2018-08-28
CA3210794A1 (en) 2016-05-19
DK3217963T3 (da) 2020-07-20
US12343348B2 (en) 2025-07-01
HK1243954A1 (en) 2018-07-27
AU2015346196B2 (en) 2019-01-31
JP6709226B2 (ja) 2020-06-10

Similar Documents

Publication Publication Date Title
JP7645913B2 (ja) プラダー－ウィリ症候群またはスミス－マゲニス症候群を有する対象を処置するための方法
JP2008510835A (ja) カリウムａｔｐチャンネル開放因子の製剤処方、及びその使用
US9757384B2 (en) Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
NZ731565B2 (en) Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome